Diet-induced obese alters the expression and function of hepatic drug-metabolizing enzymes and transporters in rats

Gadde, 2018, Obesity: pathophysiology and management, J. Am. Coll. Cardiol., 71, 69, 10.1016/j.jacc.2017.11.011 Harms, 2013, Brown and beige fat: development, function and therapeutic potential, Nat. Med., 19, 1252, 10.1038/nm.3361 Jeon, 2014, Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management, Endocrinol. Metab. (Seoul)., 29, 410, 10.3803/EnM.2014.29.4.410 Hanley, 2010, Effect of obesity on the pharmacokinetics of drugs in humans, Clin. Pharmacokinet., 49, 71, 10.2165/11318100-000000000-00000 Corsini, 2013, Drug-induced liver injury: the role of drug metabolism and transport, J. Clin. Pharmacol., 53, 463, 10.1002/jcph.23 Gay, 2017, Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: a focus on cytochrome P450, transporters, and acid suppression therapy, Hematol. Oncol., 35, 259, 10.1002/hon.2335 Lu, 2017, CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research, Sci. Rep., 7, 42922, 10.1038/srep42922 Rowland, 2013, The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification, Int. J. Biochem. Cell Biol., 45, 1121, 10.1016/j.biocel.2013.02.019 Dlugosz, 2016, ABC transporters in the development of multidrug resistance in cancer therapy, Curr. Pharm. Des., 22, 4705, 10.2174/1381612822666160302103646 Vauthier, 2017, Targeted pharmacotherapies for defective ABC transporters, Biochem. Pharmacol., 136, 1, 10.1016/j.bcp.2017.02.020 Brill, 2012, Impact of obesity on drug metabolism and elimination in adults and children, Clin. Pharmacokinet., 51, 277, 10.2165/11599410-000000000-00000 Woolsey, 2015, CYP3A activity and expression in nonalcoholic fatty liver disease, Drug Metab. Dispos., 43, 1484, 10.1124/dmd.115.065979 Maximos, 2017, Tissue specific modulation of cyp2c and cyp3a mRNA levels and activities by diet-induced obesity in mice: the impact of Type 2 diabetes on drug metabolizing enzymes in liver and extra-hepatic tissues, Pharmaceutics, 9, E40, 10.3390/pharmaceutics9040040 Shu, 2016, Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp3a and Oatp2, Xenobiotica, 46, 875, 10.3109/00498254.2016.1141437 Wang, 2016, Characterization of novel cytochrome P450 2E1 knockout rat model generated by CRISPR/Cas9, Biochem. Pharmacol., 105, 80, 10.1016/j.bcp.2016.03.001 Chen, 2016, Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach, Sci. Rep., 6, 28482, 10.1038/srep28482 Seo, 2014, In vitro assay of six UDP-glucuronosyltransferase isoforms in human liver microsomes, using cocktails of probe substrates and liquid chromatography-tandem mass spectrometry, Drug Metab. Dispos., 42, 1803, 10.1124/dmd.114.058818 Chen, 2018, Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes, Toxicol. Lett., 295, 379, 10.1016/j.toxlet.2018.07.021 Chai, 2013, Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond, Exp. Opin. Drug Metab. Toxicol., 9, 253, 10.1517/17425255.2013.754010 Amacher, 2016, The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors, Exp. Opin. Drug Metab. Toxicol., 12, 1463, 10.1080/17425255.2016.1223626 Gerbal-Chaloin, 2013, Nuclear receptors in the cross-talk of drug metabolism and inflammation, Drug Metab. Rev., 45, 122, 10.3109/03602532.2012.756011 Li, 2018, Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease, Toxicology, 410, 199, 10.1016/j.tox.2018.08.007 Evans, 1999, Pharmacogenomics: translating functional genomics into rational therapeutics, Science, 286, 487, 10.1126/science.286.5439.487 Rasmussen, 1997, Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans, Br. J. Clin. Pharmacol., 43, 253, 10.1111/j.1365-2125.1997.00546.x Vaghela, 2017, In vivo pharmacokinetic interaction by ethanolic extract of Gymnema sylvestre with CYP2C9 (Tolbutamide), CYP3A4 (Amlodipine) and CYP1A2 (Phenacetin) in rats, Chem. Biol. Interact., 278, 141, 10.1016/j.cbi.2017.10.015 Guest, 2018, Caffeine, CYP1A2 Genotype, and Endurance Performance in Athletes, Med. Sci. Sports Exerc., 50, 1570, 10.1249/MSS.0000000000001596 Ghose, 2011, Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters, Life Sci., 89, 57, 10.1016/j.lfs.2011.05.005 Oh, 2012, Hepatic expression of cytochrome P450 in type 2 diabetic Goto-Kakizaki rats, Chem. Biol. Interact., 195, 173, 10.1016/j.cbi.2011.12.010 Caraco, 1995, Caffeine pharmacokinetics in obesity and following significant weight reduction, Int. J. Obes. Relat. Metab. Disord., 19, 234 Rossner, 2017, Flavin-containing monooxygenases in aging and disease: Emerging roles for ancient enzymes, J. Biol. Chem., 292, 11138, 10.1074/jbc.R117.779678 Oda, 2015, A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development, Drug Metab. Pharmacokinet., 30, 30, 10.1016/j.dmpk.2014.12.001 Thakkar, 2017, Effect of liver disease on hepatic transporter expression and function, J. Pharm. Sci., 106, 2282, 10.1016/j.xphs.2017.04.053